A team has found immune cells in the lungs after infection from the flu, which protected mice against reinfection from a different strain.
List view / Grid view
Filter the results
New insights into the mechanisms of anti-OX40 antibodies could enable their therapeutic activity to be manipulated to treat different tumours.
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
A new analysis suggests SARS-CoV-2-specific antibodies remain relatively stable for eight months and Spike protein-specific memory B cells increase in number over time.
A new study suggests that inflammation and blood vessel damage may be the primary causes of neurological symptoms in COVID-19 patients, instead of the virus infecting the brain.
Associate Professor Pandurangan Vijayanand from La Jolla Institute for Immunology discusses his study into the body’s immune response to SARS-CoV-2 and why this can vary.
Using CRISPR-Cas9, scientists have developed a new method for generating mouse lines for vaccine research in just a few weeks.
New research has demonstrated in mouse models that the SHP-1 protein limits the capacity of dendritic cells, making it a target for a leishmaniasis vaccine.
New research has provided a metabolic atlas for insights into obesity and tumours' ability to hide from the immune system.
Researchers from Massachusetts General Hospital have studied several thousand circulating proteins within the plasma proteome of symptomatic COVID-19 patients and acutely ill non-COVID-19 controls. Nikki Withers discussed their findings and implications of the study with one of the lead authors, Dr Mike Filbin.
Researchers studied 180 convalescent COVID-19 patients to reveal T-cell epitopes that they say can be targeted by a vaccine.
New research has shown that MAIT cells are strongly activated in people with moderate to severe COVID-19 disease.
Researchers have discovered how Tregs can reduce spinal cord injury caused by diseases like multiple sclerosis (MS).
Regulatory T cells (Tregs) play a key role in regulating our immune system and inflammatory processes. Sangamo Therapeutics is evaluating the potential of CAR-Tregs (Tregs genetically modified with a chimeric antigen receptor, or CAR) for the development of therapies for immunological diseases, such as Crohn’s disease and multiple sclerosis, as…
Not every step of CAR T-cell manufacturing can be tightly regulated, introducing some significant quality control challenges for companies developing CAR T cancer therapies